Pascal Girard

3.6k total citations
102 papers, 2.3k citations indexed

About

Pascal Girard is a scholar working on Oncology, Statistics and Probability and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Pascal Girard has authored 102 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 25 papers in Statistics and Probability and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Pascal Girard's work include Statistical Methods in Clinical Trials (24 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lung Cancer Treatments and Mutations (10 papers). Pascal Girard is often cited by papers focused on Statistical Methods in Clinical Trials (24 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lung Cancer Treatments and Mutations (10 papers). Pascal Girard collaborates with scholars based in France, Switzerland and United States. Pascal Girard's co-authors include Brigitte Tranchand, Michel Tod, Christian Laveille, Gilles Freyer, Sylvie Chabaud, Helen Kastrissios, Terrence F. Blaschke, Nadia Terranova, Lewis B. Sheiner and Akash Khandelwal and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Pascal Girard

100 papers receiving 2.2k citations

Peers

Countries citing papers authored by Pascal Girard

Since Specialization

Citations

This map shows the geographic impact of Pascal Girard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Girard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Girard more than expected).

Fields of papers citing papers by Pascal Girard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Girard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Girard. The network helps show where Pascal Girard may publish in the future.

Co-authorship network of co-authors of Pascal Girard

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Girard. A scholar is included among the top collaborators of Pascal Girard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Girard. Pascal Girard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Modeling tumor size dynamics based on real‐world electronic health records and image data in advanced melanoma patients receiving immunotherapy 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Perrine Courlet, Daniel Abler, Monia Guidi, Pascal Girard, Federico Amato, Naïk Vietti Violi, (unknown), (unknown), Alexandre Wicky, Sofiya Latifyan, (unknown), Mario Jreige, Clarisse Dromain, Chantal Csajka, John O. Prior, Karthik Venkatakrishnan, Olivier Michielin, Michel A. Cuendet, Nadia Terranova	7
2	Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non‐small cell lung cancer based on bintrafusp alfa trials 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Nadia Terranova, Diane R. Mould, Yulia Vugmeyster, (unknown), (unknown), Pascal Girard, Karthik Venkatakrishnan, Akash Khandelwal	4
3	A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), (unknown), Sreenath M. Krishnan, Siv Jönsson, Lena E. Friberg, Pascal Girard, Karthik Venkatakrishnan, Yulia Vugmeyster, Akash Khandelwal, Mats O. Karlsson	5
4	Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient‐level placebo (Standard‐of‐Care) data to enable model‐informed drug development 2022 ·CPT Pharmacometrics & Systems Pharmacology ·Kosalaram Goteti, Jonathan French, (unknown), Ying Li, Florence Casset‐Semanaz, Aida Aydemir, Robert Townsend, (unknown), Matthew Studham, (unknown), Amy Kao, Marc R. Gastonguay, Pascal Girard, Lisa J. Benincosa, Karthik Venkatakrishnan	7
5	584P Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours 2020 ·Annals of Oncology ·Paul K. Paik, (unknown), (unknown), (unknown), Orestis Papasouliotis, Richard Anziano, Karin Berghoff, Andreas Johne, Pascal Girard, Rainer Strotmann	5
6	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors 2019 ·Clinical Cancer Research ·Gerald S. Falchook, Razelle Kurzrock, Hesham M. Amin, (unknown), Siqing Fu, Sarina A. Piha‐Paul, Filip Jankú, Ghazaleh Eskandari, Daniel V.T. Catenacci, Manfred Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese‐Hamim, Pascal Girard, Samer El Bawab, David S. Hong	67
7	Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients 2018 ·Cancer Chemotherapy and Pharmacology ·Olivia Le Saux, Aurélie Bourmaud, Catherine Rioufol, Olivier Colomban, Jérôme Guitton, Vérane Schwiertz, Véronique Régnier Denois, Benoît You, Florence Ranchon, (unknown), Pascal Girard, Franck Chauvin, Gilles Freyer, Michel Tod, Émilie Hénin, V. Trillet-Lenoir	15
8	Adherence to oral anticancer chemotherapy: What influences patients’ over or non-adherence? Analysis of the OCTO study through quantitative–qualitative methods 2015 ·BMC Research Notes ·Aurélie Bourmaud, Émilie Hénin, Fabien Tinquaut, Véronique Régnier Denois, (unknown), Olivier Colomban, Benoît You, Florence Ranchon, Jérôme Guitton, Pascal Girard, Gilles Freyer, Michel Tod, Catherine Rioufol, V. Trillet-Lenoir, Franck Chauvin	21
9	Links Between Cyclosporin Exposure in Tissues and Graft-Versus-Host Disease in Pediatric Bone Marrow Transplantation: Analysis by a PBPK Model 2010 ·Pharmaceutical Research ·(unknown), Nathalie Bleyzac, Pascal Girard, Gilles Freyer, Yves Bertrand, Michel Tod	13
10	Predictive Value of Modeled AUCAFP-hCG, a Dynamic Kinetic Parameter Characterizing Serum Tumor Marker Decline in Patients With Nonseminomatous Germ Cell Tumor 2010 ·Urology ·Benoît You, (unknown), Helen Boyle, Jean‐Pierre Droz, Pascal Girard, Brigitte Tranchand, Benjamin Ribba, Michel Tod, Sylvie Chabaud, (unknown), Aude Fléchon	10
11	Development of a drug–disease simulation model for rituximab in follicular non‐Hodgkin's lymphoma 2009 ·British Journal of Clinical Pharmacology ·David Ternant, Émilie Hénin, Guillaume Cartron, Michel Tod, Gilles Paintaud, Pascal Girard	16
12	Exposure-Effect Population Model of Inolimomab, a Monoclonal Antibody Administered in First-Line Treatment for Acute Graft-Versus-Host Disease 2007 ·Clinical Pharmacokinetics ·(unknown), Gilles Freyer, Mauricette Michallet, (unknown), (unknown), (unknown), Claudine Vermot‐Desroches, Brigitte Tranchand, Pascal Girard	10
13	Clinical Trial Simulation: A Tool for Understanding Study Failures and Preventing Them 2005 ·Basic & Clinical Pharmacology & Toxicology ·Pascal Girard	30
14	Simulation des essais cliniques dans le développement des médicaments 2004 ·Therapies ·Pascal Girard, Michel Cucherat, David Guez, Jean‐Pierre Boissel, Sylvain Durrleman, (unknown), Christian Laveille, (unknown), (unknown), (unknown), Gilles Paintaud, (unknown), Michael Tansey, (unknown), Jean‐Marc Tréluyer, (unknown), (unknown)	10
15	Clinical Trial Simulation in Drug Development 2004 ·Therapies ·Pascal Girard, Michel Cucherat, David Guez, Jean‐Pierre Boissel, Sylvain Durrleman, (unknown), Christian Laveille, (unknown), (unknown), (unknown), Gilles Paintaud, (unknown), Michael Tansey, (unknown), Jean‐Marc Tréluyer, (unknown), (unknown)	12
16	Inter‐Study Variability in Population Pharmacokinetic Meta‐Analysis: When and how to Estimate It? 2000 ·Journal of Pharmaceutical Sciences ·S Laporte‐Simitsidis, Pascal Girard, Patrick Mismetti, Sylvie Chabaud, Hervé Decousus, Jean‐Pierre Boissel	38
17	A Markov mixed effect regression model for drug compliance 1998 ·Statistics in Medicine ·Pascal Girard, Terrence F. Blaschke, Helen Kastrissios, Lewis B. Sheiner	70
18	Heterogeneous Effect of Quinidine on the Ventricular Depolarization Process Assessed by the Spatial Velocity Electrocardiogram of the QRS Complex 1996 ·Cardiology ·Samir Fareh, P Arnaud, Jocelyne Fayn, Patrice Nony, Pascal Girard, Margaret Haugh, (unknown), (unknown), Jean Boissel, P. Rubel	1
19	Do we need full compliance data for population pharmacokinetic analysis? 1996 ·Journal of Pharmacokinetics and Biopharmaceutics ·Pascal Girard, Lewis B. Sheiner, Helen Kastrissios, Terrence F. Blaschke	56
20	Population pharmacokinetics of midazolam in neonates 1994 ·Clinical Pharmacology & Therapeutics ·P Burtin, Évelyne Jacqz-Aigrain, Pascal Girard, R Lenclen, Jean‐François Magny, P. Bétrémieux, (unknown), L. Desplanques, P. Mussat	113

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact